LEMAITRE VASCULAR INC

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

LMAT$79.02-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

	Issuer Purchases of Equity Securities
Maximum Number
(or Approximate
Total Number of · Dollar Value) of
Shares (or Units) · Shares (or Units)
	Total	Average	Purchased as	that may yet be
	Number of	Price	Part of Publicly	Purchased under
	Shares (or Units)	Paid Per	Announced Plans	the Plans or
Period	Purchased (1)	Share (or Unit)	or Program	Program (2)
January 1, 2025 through January 31, 2025	3,693	$100.09	N/A	$75,000,000
February 1, 2025 through February 28, 2025	2,280	$92.30	N/A	$75,000,000
March 1, 2025 through March 31, 2025	92	$88.63	N/A	$75,000,000
Total	6,065	$96.99	N/A

(1)	For the three months ended March 31, 2025, we repurchased 6,065 shares of our common stock to satisfy employees’ obligations with respect to minimum statutory withholding taxes in connection with the vesting of restricted stock units and performance-based restricted stock units.

(2)	On February 18, 2025, our Board of Directors authorized the repurchase of up to $75.0 million of our common stock through transactions on the open market, in privately negotiated transactions or otherwise until February 17, 2026. To date, we have not made any repurchases under this program.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.